公开(公告)号：US10738054B2

公开(公告)日：2020-08-11

申请号：US15992529

申请日：2018-05-30

申请人： Metys Pharmaceuticals AG

发明人： Michael Scherz ,  Carlo Farina

IPC分类号： C07D487/04 ,  A61K45/06 ,  A61K31/4188 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/708 ,  A61P25/02 ,  A61P19/02 ,  A61P25/24 ,  A61K31/282 ,  A61K31/407

摘要： The present invention relates to a composition of enantiomers of 3,6,7,7a-tetrahydro-1H-pyrrolo[1,5-a]imidazole-2,5-dione and pharmaceutically acceptable solvates or co-crystals thereof in a certain ratio, a pharmaceutical composition comprising said composition, its use as a medicament and the use of the inventive compositions or pharmaceutical compositions in the treatment and/or prevention of a disease or disorder typically and preferably selected from peripheral sensory neuropathy, preferably peripheral neuropathic pain; seizure; depression; or cognitive impairment.

公开(公告)号：US10729711B2

公开(公告)日：2020-08-04

申请号：US16329126

申请日：2017-08-30

申请人： University of Pittsburgh-Of the Commonwealth System of Higher Education

发明人： Edwin K. Jackson ,  Stevan P. Tofovic

IPC分类号： A61K31/708 ,  A61K31/522 ,  A61P7/00 ,  A61P3/10 ,  A61P11/00 ,  A61P7/02 ,  A61K45/06 ,  A61P25/28 ,  A61K31/4965 ,  A61P31/18 ,  A61P9/12 ,  A61P9/04 ,  A61P13/00

摘要： Herein, 8-substituted guanine and/or 8-substituted guanosine compounds are used in methods to treat hypertension (such as systemic or pulmonary hypertension), stroke, diabetes, and/or patients in need of a diuretic. In addition, 8-substituted guanine and/or 8-substituted guanosine compounds are included in a beverage composition, which can be a fermented beverage, such as wine. Further, purine nucleoside phosphorylase (PNPase) inhibitors (such as 8-substituted guanine and/or 8-substituted guanosine) and/or PNPase purine nucleoside substrates (such as guanosine and/or inosine) can be used in methods of treating or reducing the risk of pulmonary hypertension (PH), such as PH associated with HIV or sickle cell disease (SCD). PNPase inhibitors (such as 8-substituted guanine and/or 8-substituted guanosine) and/or PNPase purine nucleoside substrates (such as guanosine and/or inosine) can also be used in methods of treating SCD or reducing sickling of red blood cells (RBCs).

公开(公告)号：US10696708B2

公开(公告)日：2020-06-30

申请号：US15895872

申请日：2018-02-13

申请人： Janssen BioPharma, Inc.

发明人： Natalia Dyatkina ,  Guangyi Wang ,  Leonid Beigelman ,  Vivek Kumar Rajwanshi

IPC分类号： A01N43/04 ,  A61K31/70 ,  C07H19/06 ,  C07H19/20 ,  C07H19/16 ,  C07H19/10 ,  A61K31/7072 ,  A61K31/7068 ,  A61K31/708 ,  A61K45/06 ,  A61K31/7076

摘要： Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection, with a nucleoside, a nucleotide and an analog thereof.

公开(公告)号：US20190388336A1

公开(公告)日：2019-12-26

申请号：US16310511

申请日：2017-06-15

申请人： MERCK SHARP & DOHME CORP.

发明人： Stephanie Elizabeth Barrett ,  Marian E. Gindy ,  Li Li ,  Seth P. Forster ,  Ryan S. Teller

IPC分类号： A61K9/00 ,  A61K47/34 ,  A61K31/708 ,  A61P31/18

摘要： This invention relates to novel implant drug delivery systems for long-acting delivery of antiviral drugs. These compositions are useful for the treatment or prevention of human immunodeficiency virus (HIV) infection.

公开(公告)号：US20190321366A1

公开(公告)日：2019-10-24

申请号：US16201221

申请日：2018-11-27

申请人： Gilead Sciences, Inc.

发明人： Manoj C. Desai ,  Randall L. Halcomb ,  Paul Hrvatin ,  Hon Chung Hui ,  Ryan McFadden ,  Paul A. Roethle ,  Hong Yang

IPC分类号： A61K31/519 ,  A61K38/21 ,  C07D475/06 ,  A61K38/16 ,  A61K31/708 ,  A61K31/7072 ,  A61K31/7056 ,  A61K31/683 ,  A61K31/573 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/551 ,  A61K31/527 ,  C07D475/08 ,  C07D475/12 ,  C07D487/04 ,  C07D475/10 ,  C07D403/12

摘要： Provided are modulators of TLRs of Formula II: pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

公开(公告)号：US10420761B2

公开(公告)日：2019-09-24

申请号：US14773906

申请日：2014-03-17

申请人： UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED

发明人： Maria Zajac-Kaye ,  Lidia Kulemina

IPC分类号： A61K31/505 ,  A61K31/472 ,  A61K31/137 ,  A61K31/352 ,  A61K31/404 ,  A61K31/4196 ,  A61K31/429 ,  A61K31/44 ,  A61K31/4468 ,  A61K31/451 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/515 ,  A61K31/519 ,  A61K31/575 ,  A61K31/708 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/48 ,  A61K31/522 ,  A61K31/573 ,  A61K31/7072 ,  A61K31/7076 ,  A61K45/06 ,  C07D213/77 ,  C07D217/20 ,  C07D239/48 ,  C07D405/12

摘要： The current invention is directed to a class of compounds that inhibit the function of Thymidylate synthase. Thymidylate synthase inhibition was noted to result in inhibition of tumor cell grow and killing of tumor cells. Thymidylate synthase inhibition is, thus, useful for treatment of various types of cancers, including but not limited to, acute lymphoblatic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), acute monocytic leukemia (AMOL), hairy cell leukemia, large cell immunoblastic lymphoma, plasmacytoma, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, brain cancer, lung cancer, central nervous system (CNS) cancer, melanoma, renal cancer, prostate cancer, colon cancer, ovarian cancer and breast cancer. The compounds disclosed herein can be used alone or in combination with other cancer treatment regimens (e.g., radiation therapy and/or other chemotherapeutic agents that are administered to a subject having a tumor, cancer or neoplasia).

公开(公告)号：US20190269775A1

公开(公告)日：2019-09-05

申请号：US16348567

申请日：2017-11-14

申请人： Dana-Farber Cancer Institute, Inc. ,  Beth Israel Deaconess Medical Center

发明人： David Avigan ,  Jacalyn Rosenblatt ,  Donald Kufe

IPC分类号： A61K39/395 ,  A61K35/13 ,  A61K35/15 ,  A61K31/454 ,  A61K31/4035 ,  A61K31/708 ,  A61K31/7068 ,  A61K31/7125 ,  A61K39/08 ,  A61K45/06 ,  C12N5/16

摘要： The present invention provides compositions and methods for treating cancer.

公开(公告)号：US20190247469A1

公开(公告)日：2019-08-15

申请号：US16315132

申请日：2017-07-06

申请人： Building Block Nutritionals, LLC

发明人： James McGrath ,  Paul Manning ,  Eugene Scavola

IPC分类号： A61K38/38 ,  A23L33/19 ,  A23L33/12 ,  A23L33/125 ,  A23L33/13 ,  A23L33/16 ,  A23L33/155 ,  A23L33/26 ,  A23L33/18 ,  A23L33/00 ,  A61K38/40 ,  A61K31/7016 ,  A61K31/05 ,  A61K31/202 ,  A61K31/702 ,  A61K31/7004 ,  A61K38/17 ,  A61K31/201 ,  A61K31/14 ,  A61K31/205 ,  A61K31/685 ,  A61K31/015 ,  A61K31/185 ,  A61K31/375 ,  A61K31/355 ,  A61K31/203 ,  A61K31/455 ,  A61K31/593 ,  A61K31/197 ,  A61K31/122 ,  A61K31/51 ,  A61K31/525 ,  A61K31/519 ,  A61K31/4188 ,  A61K31/714 ,  A61K33/42 ,  A61K33/00 ,  A61K33/14 ,  A61K31/194 ,  A61K33/04 ,  A61K33/26 ,  A61K33/30 ,  A61K33/34 ,  A61K33/32 ,  A61K31/7076 ,  A61K31/7068 ,  A61K31/708 ,  A61K31/7072 ,  A61K31/718 ,  A61K31/733 ,  A61K9/00

CPC分类号： A61K38/38 ,  A23L33/00 ,  A23L33/10 ,  A23L33/115 ,  A23L33/12 ,  A23L33/125 ,  A23L33/13 ,  A23L33/155 ,  A23L33/16 ,  A23L33/17 ,  A23L33/18 ,  A23L33/19 ,  A23L33/26 ,  A23L33/40 ,  A23V2002/00 ,  A61K9/0053 ,  A61K31/015 ,  A61K31/05 ,  A61K31/122 ,  A61K31/14 ,  A61K31/185 ,  A61K31/194 ,  A61K31/197 ,  A61K31/201 ,  A61K31/202 ,  A61K31/203 ,  A61K31/205 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/685 ,  A61K31/7004 ,  A61K31/7016 ,  A61K31/702 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/714 ,  A61K31/718 ,  A61K31/733 ,  A61K33/00 ,  A61K33/04 ,  A61K33/14 ,  A61K33/26 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34 ,  A61K33/42 ,  A61K38/1709 ,  A61K38/40 ,  A23V2200/30 ,  A23V2200/32 ,  A23V2200/324 ,  A23V2200/332

摘要： The present disclosure provides a nutritional formula comprising alpha-lactalbumin enriched whey protein concentrate; beta-casein enriched milk protein; mildly hydrolyzed milk protein; osteopontin; lactoferrin; oleic acid-palmitic acid-oleic acid triglyceride, wherein palmitic acid is at the SN-2 position of the glycerol backbone of the triglyceride; lactose, wherein the lactose is reduced lactose; lutein; docosahexanoic acid; arachidonic acid; galactooligosaccharides; and polydextrose. The provided nutritional formulas may be useful in providing nutrition and/or promoting postnatal development of a subject (e.g., promoting postnatal development of an infant's gastrointestinal functions, nutrient absorption, immune system development, etc.). Also provided are powder forms, reconstituted formulas, kits, methods, and uses that include or involve a nutritional formula described herein.

公开(公告)号：US10370401B2

公开(公告)日：2019-08-06

申请号：US15790764

申请日：2017-10-23

申请人： Alios BioPharma, Inc.

发明人： Leonid Beigelman ,  Guangyi Wang ,  David Bernard Smith ,  Marija Prhavc ,  Christian Andreas Jekle ,  Jerome Deval

IPC分类号： A61K31/7076 ,  A61K31/708 ,  C07H19/20 ,  C07H19/06 ,  C07H19/16 ,  C07H19/10 ,  A61K31/7064 ,  A61K31/7052 ,  A61K31/7072 ,  C07H19/11 ,  C07H19/207 ,  C07H19/213

摘要： Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs.

公开(公告)号：US10335427B2

公开(公告)日：2019-07-02

申请号：US16060412

申请日：2017-05-16

申请人： Jianping Cai

发明人： Jianping Cai ,  Zhenhe Wang ,  Jin Li ,  Yunxuan Li ,  Ping Jiang ,  Ju Cui

IPC分类号： A61K31/708 ,  A61P35/04 ,  A61P35/00 ,  A61P35/02

摘要： The present invention discloses a medicament for the prevention and treatment of tumors, in particular relating to the use of 8-oxo-deoxyguanosine triphosphate (8-oxo-dGTP) in the manufacturing of a medicament for the prevention and treatment of tumors, and a medicament comprising 8-oxo-dGTP for the prevention and treatment of tumors, and falls within the pharmaceutical field. The 8-oxo-dGTP can be used in the manufacturing of a medicament for at least one of the treatment, prevention and control of tumors. The 8-oxo-dGTP has a significant inhibitory effect on tumorigenesis and tumor cell proliferation for many types of tumors, and can serve as a new candidate medicament for the prevention and treatment of tumors. Animal experiments show that the 8-oxo-dGTP is significantly superior to 5-FU in terms of tumor inhibition, therefore has a good industrial availability and great business and social values.